Transoma Medical Announces First Patient Enrollment in Clinical Study to Evaluate Recurrence of Atrial Fibrillation Post Catheter Ablation
7/28/2009 10:34:40 AM
ST. PAUL, Minn.--(BUSINESS WIRE)--Transoma Medical, Inc., manufacturer of Sleuth AT™, the only wireless, automated implantable cardiac monitoring system with programmable and frequent electrocardiogram (ECG) sampling, announced the first patient enrollment and implant in a long-term study to monitor patients who have been prescribed catheter ablation therapy for atrial fibrillation (AF) at risk of recurrence of AF after the procedure. The implant was performed on July 27, 2009, by Dr. Safwat Gassis, a cardiac electrophysiologist with Associated Cardiologists in Harrisburg, Pa. The primary investigator for the study at Harrisburg Hospital, part of the Pinnacle Health System, is Dr. David Scher, director of cardiac electrophysiology for Pinnacle Health System and Associated Cardiologists. The company received FDA 510(k) marketing clearance for Sleuth AT, its next-generation product, on Feb. 11, 2009.
comments powered by